Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK. Our personalised cancer DNA profiling is used to precisely identify the most appropriate clinical targeted therapies and/or immunotherapies which can be used to treat patients as an alternative to chemotherapy. Our molecular Next Generation Sequencing capabilities are used to sequence tumour DNA and Covid-19/ SARS-CoV-2 for virus mutations. SARS-CoV-2 testing, and sequencing is used to identify high risk Covid-19 variants which can potentially bypass the vaccine. Oncologica’s NGS DNA profiling covers 505 genes with linkage to over 750 targeted therapies to provide patients and clinicians with detailed genomic blueprints that optimize therapy choices and improve outcomes. Oncologica also undertakes Contract Research supporting biomarker development programmes, clinical trials, and the validation of new diagnostic testing platforms. Our in-house R&D activities focus on the development of novel cancer genomic based diagnostic and therapeutic approaches. Our government approved Oncofocus and Coronofocus lab tests are used by healthcare providers the private sector, businesses, transport, and educational institutions. Personalised genomic data helps empower patients and clinicians to increase treatment efficacy and improve human health.
View Top Employees from Oncologica UKWebsite | http://www.oncologica.com/ |
Revenue | $3 million |
Employees | 71 (71 on RocketReach) |
Founded | 2014 |
Phone | +44 1223 785327 |
Technologies |
JavaScript,
HTML,
PHP
+35 more
(view full list)
|
Industry | Hospitals and Health Care, Medical Testing & Clinical Laboratories, Precision Oncology, Healthcare, Molecular Pathology, Cancer Treatments, Tumour Profiling, Targeted Therapies, Next Generation Sequencing NGS, DNA & RNA Analysis, Immunotherapy, Molecular tissue analytics, Research and Development, Drug Discovery |
Competitors | CTOAM | Cancer Treatment Options & Management, Medicor Cancer Centres Inc, Syreon: Celebrating 20 Years of Leading Research |
SIC | SIC Code 80 Companies, SIC Code 807 Companies |
NAICS | NAICS Code 6215 Companies, NAICS Code 62151 Companies, NAICS Code 62 Companies, NAICS Code 621 Companies |
Looking for a particular Oncologica UK employee's phone or email?
The Oncologica UK annual revenue was $3 million in 2024.
Marco Loddo is the Co-Founder and Scientific Director of Oncologica UK.
71 people are employed at Oncologica UK.
The NAICS codes for Oncologica UK are [6215, 62151, 62, 621].
The SIC codes for Oncologica UK are [80, 807].